5-Amino-1MQ vs Retatrutide
A side-by-side research comparison of 5-Amino-1MQ and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | 5-Amino-1MQ | Retatrutide |
|---|---|---|
| Full name | 5-Amino-1-Methylquinolinium (NNMT Inhibitor) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | Inhibits NNMT enzyme, preventing methylation and degradation of nicotinamide. Increases intracellular NAD+ pools, activates sirtuins, and reduces fat cell size without affecting food intake. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 173.2 Da | 5,200 Da (approximate) |
| Half-life | 8-12 hours | 6 days |
| Bioavailability | High (oral) | High (SubQ) |
| Typical dose | 50-100 mg | 1-2 mg → titrate up to 12 mg |
| Frequency | 1-2x daily | Once weekly |
| Route | Oral (capsule) | Subcutaneous injection |
5-Amino-1MQ reported benefits
- Increased cellular energy metabolism
- Reduced fat cell size
- Elevated NAD+ levels
- Does not suppress appetite
- Improved muscle stem cell function
- Oral convenience
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.